Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Chromadex Corp CS (NQ: CDXC ) 3.090 +0.020 (+0.65%) Streaming Delayed Price Updated: 9:48 AM EDT, Jul 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 17,066 Open 3.070 Bid (Size) 3.070 (1) Ask (Size) 3.110 (1) Prev. Close 3.070 Today's Range 3.028 - 3.090 52wk Range 1.250 - 4.650 Shares Outstanding 68,196,526 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 July 24, 2024 From ChromaDex Corporation Via Business Wire ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs) July 23, 2024 From ChromaDex Corporation Via Business Wire Performance YTD +116.08% +116.08% 1 Month +13.19% +13.19% 3 Month -13.20% -13.20% 6 Month +99.35% +99.35% 1 Year +79.65% +79.65% More News Read More CDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023 March 06, 2024 Via InvestorPlace Earnings Preview For ChromaDex March 05, 2024 Via Benzinga ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel July 22, 2024 From ChromaDex Corporation Via Business Wire ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August July 16, 2024 From ChromaDex Corporation Via Business Wire ChromaDex to Join Russell 2000® Index July 01, 2024 From ChromaDex Corporation Via Business Wire Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD) June 24, 2024 From ChromaDex Corporation Via Business Wire ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) June 13, 2024 From ChromaDex Corporation Via Business Wire Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 07, 2024 Via Benzinga ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT) June 07, 2024 From ChromaDex Corporation Via Business Wire ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024 June 04, 2024 From ChromaDex Corporation Via Business Wire ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 May 23, 2024 From ChromaDex Corporation Via Business Wire ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award May 22, 2024 From ChromaDex Corporation Via Business Wire CDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024 May 08, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Wednesday's After-Market Session May 08, 2024 Via Benzinga ChromaDex Corporation Reports First Quarter 2024 Financial Results May 08, 2024 From ChromaDex Corporation Via Business Wire ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® April 25, 2024 From ChromaDex Corporation Via Business Wire ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement April 30, 2024 From ChromaDex Corporation Via Business Wire ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 April 24, 2024 From ChromaDex Corporation Via Business Wire ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market April 23, 2024 From ChromaDex Corporation Via Business Wire ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program March 26, 2024 From ChromaDex Corporation Via Business Wire 12 Health Care Stocks Moving In Monday's Intraday Session March 18, 2024 Via Benzinga ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results March 06, 2024 From ChromaDex Corporation Via Business Wire Earnings Scheduled For March 6, 2024 March 06, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
